Phenylketonuria in Pediatric Neurology Practice: A Series of 146 Cases

Abstract

The neurologic manifestations of patients with phenylketonuria treated at different ages are illustrated in this series of 146 cases, including 9 sib pairs. In addition to well-known findings such as mental retardation, autistic features, microcephaly, and tremor, motor retardation was common and responded promptly to dietary treatment. Hypotonia and diminished reflexes were more frequent findings than hypertonia. Four sib pairs showed divergent features, such as the later-treated sibling having higher function than the early-treated one. Because siblings have a similar genotype and similar environmental and dietary conditions, this observation can be explained by differences in phenylalanine transport to the brain or additional metabolic or perinatal factors influencing the neurologic outcome. (J Child Neurol 2006;21:987—990; DOI 10.2310/7010.2006.00228).

Get full access to this article

View all access options for this article.

References

Ozalp I. , Coskun T. , Tokatli A. , et al: Newborn phenylketonuria screening in Turkey: At present and organization for future. Turk J Pediatr 2001 ;43:97—101.

Koch RK : Issues in newborn screening for phenylketonuria. Am Fam Physician 1999;60:1462—1466.

Ozguc M. , Ozalp I. , Coskun T. , et al: Mutation analysis in Turkish phenylketonuria patients. J Med Genet 1993;30:129—130.

Holtzman C. , Slazyk WE , Cordero JF , Hannon WH : Descriptive epidemiology of missed cases of phenylketonuria and congenital hypothyroidism. Pediatrics 1986;78:553—558.

Khazipov R. , Sirota A. , Leinekugel X. , et al: Early motor activity drives spindle bursts in the developing somatosensory cortex. Nature 2004; 432:758—761.

Nagatsu T. , Ichinose H. : Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin . Mol Neurobiol 1999;19:79—96.

Brenton DP , Pietz J. : Adult care in phenylketonuria and hyperphenylalaninaemia: The relevance of neurological abnormalities. Eur J Pediatr 2000;159 (Suppl 2):S114—S120.

Azen C. , Koch R. , Friedman E. , et al: Summary of findings from the United States Collaborative Study of children treated for phenylketonuria. Eur J Pediatr 1996;155 (Suppl 1):S29—S32.

Waisbren SE , Brown MJ , de Sonneville LM , Levy HL : Review of neuropsychological functioning in treated phenylketonuria: An information processing approach. Acta Paediatr 1994;407: 98—103.

10.

Allen RJ , Gibson RM : Phenylketonuria with normal intelligence. Am J Dis Child 1961;102:115—122.

11.

Okano Y. , Eisensmith RC , Guttler F. , et al: Molecular basis of phenotypic heterogeneity in phenylketonuria . N Engl J Med 1991; 324:1232—1238.

12.

Özalp I. , Coskun T. , Ozguc A. , et al: Genetic and neurological evaluaiton of untreated and late-treated patients with phenylketonuria. J Inherit Metab Dis 1994;17:371.

13.

Andersen AE , Avins L. : Lower brain phenylalanine levels by giving other large neutral amino acids . Arch Neurol 1976;33:684—686.

14.

Kaufman S. : Some factors relevant to the consideration of a possible alternative treatment for classical phenylketonuria. J Inherit Metab Dis 1998;21:4—19.

15.

Ramus SJ , Forrest SM , Pitt DD , Cotton RG : Genotype and intellectual phenotype in untreated phenylketonuria patients . Pediatr Res 1999; 45:474—481.

16.

Weglage J. , Wiedermann D. , Denecke J. , et al: Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria. Ann Neurol 2001;50:463—467.

17.

Holtzman NA , Meek AG , Mellits ED , Kallman CH : Neonatal screening for phenylketonuria. 3. Altered sex ratio; extent and possible causes. J Pediatr 1974;85:175—181.

18.

Leuzzi V. , Bianchi MC , Tosetti M. , et al: Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria. J Inherit Metab Dis 2000;23:563—570.

19.

Black H. : Newborn screening report sparks debate in USA. Lancet 2005;365:1453—1454.